Morgan Stanley
OCAT

Morgan Stanley’s OCATA THERAPEUTICS, INC. COMMON STOCK OCAT Stock Holding History

Morgan Stanley’s Portfolio OCAT Stock Details OCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-47,835
Closed -$403K – 6950
2015
Q4 		$403K Buy
47,835
+32,703
+216% +$219K ﹤0.01% 4689
2015
Q3 		$64K Sell
15,132
-3,671
-20% -$16K ﹤0.01% 5635
2015
Q2 		$100K Sell
18,803
-37,368
-67% -$239K ﹤0.01% 5591
2015
Q1 		$346K Buy
+56,171
New +$360K ﹤0.01% 4892

Morgan Stanley's OCAT Position: Q1 2016 in Review

Morgan Stanley sold out of OCATA THERAPEUTICS, INC. COMMON STOCK (OCAT) in Q1 2016, closing a stake of 47,835 shares — an estimated $403K sold.

Morgan Stanley first reported a position in OCAT in Q1 2015 and held it in 4 quarters. The position peaked at $403K in Q4 2015. 1 fund tracked by Wall St. Rank holds OCAT as of Q1 2016.

  • Morgan Stanley reported no remaining OCATA THERAPEUTICS, INC. COMMON STOCK position as of Q1 2016 after selling out during the quarter.
  • Morgan Stanley sold 47,835 OCATA THERAPEUTICS, INC. COMMON STOCK shares in Q1 2016, an estimated $403K.
  • Morgan Stanley first reported a position in OCATA THERAPEUTICS, INC. COMMON STOCK in Q1 2015 and held it in 4 quarters.
  • Morgan Stanley's OCATA THERAPEUTICS, INC. COMMON STOCK position peaked at $403K in Q4 2015.
  • 1 fund tracked by Wall St. Rank held OCATA THERAPEUTICS, INC. COMMON STOCK as of Q1 2016.

Based on Morgan Stanley's 13F filing for Q1 2016, filed 12 May 2016.